Calendario›SNY›FRAME
FRAME
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
Ensayo de Sanofi en Dermatitis atopica.
Más ensayos de: Dermatitis atópica.
- Fase
- no aplica
- Estado
- Reclutando pacientes
- Participantes
- 600
- Centros
- 62
- Fin del objetivo primario
- may 2027
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en feb 2025.
Qué mide
Previous and Current Treatments for Atopic Dermatitis (AD) (Baseline, month 6 and month 12) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06837454), actualizada en may 2026.